SONUÇLAR:
1- Malign efüzyon ile benign efüzyonlar aras nda istatistiksel olarak anlaml fark mevcuttu (p<0.05).
2- Malign efüzyonlar ndaki VEGF düzeyi, ayn hastalar n serum VEGF düzeyinden anlaml derecede yüksek bulunuldu (p<0.05).
3- En yüksek efüzyon VEGF ortalamas Over Ca l hastalarda ölçüldü. 4- En yüksek serum VEGF ortalamas Mezotelyama l hastalarda ölçüldü. 5- Malign asit VEGF / Benign asit VEGF düzeyi en yüksek olarak Over Ca l hastalarda oldu u görüldü.
6- Serum VEGF düzeyi ile ya aras nda ili ki saptanmad . 7- VEGF düzeyi ile cinsiyet aras nda anlaml ili ki saptanmad .
8- Serumda bak lan VEGF düzeyi ile serumda bak lan Ferritin, CA125, AFP aras nda istatistiksel olarak anlaml ili ki saptanmad .
Öneriler
1- Serum VEGF düzeyinin bak lmas , non invazif, kullan l ve basit bir yöntem olarak malign-benign asit ay r c tan s nda di er parametrelerle beraber yararl bir laboratuvar parametresi olarak kullan labilir.
2- Malign efüzyonlar n patogenezinde rol oynayan VEGF nin anti-vegf tedavi stratejilerinin geli mesi ile efüzyon tedavilerinde kullan labilmesi için deneysel çal malar n klinik çal malarla desteklenmesi gerekir.
3- Malign efüzyon olu umunda önemli role sahip olan VEGF ile ilgili geni serili çal malar bu konunun ayd nlat lmas na daha fazla k tutacakt r. 4- Tümör anjiogenezisi etyolojisinde önemli bir faktör olan VEGF nin daha fazla çal malar hak etti ini dü ünüyoruz.
7.KAYNAKLAR
1- Çakalo lu Y.Assit: etiyoloji tan , ay r c tan . Türkiye T p Dergisi.1: 41 52,1997
2- Çimen A. Periton. Anatomi. Uluda Üniversitesi Bas mevi, s:383 384,1987.
3- Bender MD. Diseases of the peritoneum. In: Cecil Textbook of Medicine, Wyngaarden JB, Smith Jr LH (eds).W.B. Saunders, Philadelphia. 1998; pp: 790 795
4- Runyon et al. Ann Intern Med 1992; 117:215 220 5- JAMA 247:1164,1982
6- Radiology 96:15,1970
7- Dinç I: Sindirim Sistemi Hastal klar in: Öbek A (ed) ç Hastal klar 4. bask Bursa Güne Kitapevi 1990;555 607
8- Bender MD. Diseases of the peritoneum. In: Cecil Textbook of Medicine, Wyngaarden JB, Smith Jr LH (eds).W.B. Saunders, Philadelphia, 1998, pp: 790 795
9- N Engl J Med 330:337,1994. Hepatology 1:249,1981 10- Hepatology 8:1104,1988
11- Ann Intern Med 117:215,1992
12- Runyon BA Ascites in liver disease n: Bockuc Gastroenterology. Eds. Habrich WS, Schafner, Berk JE. Philadelphia, WB Saunders company, 5 th edit. 1995, 2004 15
13- Kip DL Miscellaneous disease of peritoneum &mesentery n: Current diagnosis & treatment in gastroenterology. Eds. Grendell JH, Kenneth RM, Scott LF, USA. Appleton &Lange comp. 1996;143 47
14- Light RW. Pleural Diseases. 3rd ed. Baltimore: Williams & Wilkins, 1995
15- Kalayc o lu O. Plevra Hastal klar . Editör: Numano lu N. Klinik Solunum Sistemi ve Hastal klar . Ankara Ant p A. . T p Kitaplar ve Bilimsel Yay nlar, No: 29, 1997; 632 650.
16- Kinasewitz GT. Pleural Fluid Dynamics and Effusions. In: Fishman AP, Elias JA, Fishman JA, Grippi MA, Kaiser LR and Senior RM eds.
Fishman s Pulmonary Diseases and Disorders. Volume One. Third Edition. McGraw-Hill International Edition,1998;1389 1409.
17- Karakoca Y, Emri S. Plevral effüzyon. Editör: Bar Y . Solunum Hastal klar Temel Yakla m. Atlas Kitapç l k LTD. T . Ankara, üçüncü bask , 1998; 335 349
18- Özlü T. Plevral S v larda Tan . Toraks Dergisi A ustos 2000; cilt 1, say 2: 85 94.
19- Antony VB. Pleural effusions: How to Interprent the Signs. Patient Care March 2000;81 92.
20- Sadikol RT, Rogers JT, Cheng DS, Moyers P et al. Pleural Fluid Characteristics of Patients With Symptomatic Pleural Effusion After Coronery Artery Bypass Graft Surgery. Arch. Intern. Med. 2000; Vol. 160:2665 2668.
21- Metinta M, Alata Ö, Alata F, Çolak Ö et al. Comparative Analysis of Biochemical Parameters for Differentiation of Pleural Exudates from
Transudates: Light s Criteria, Cholesterol, Bilirubin, Albumin Gradient, Alkaline Phosphatase, Creatin Kinase and Uric Acid. Clinica Chimica Acta 1997;264:149 162.
22- Kömürcüo lu B, Büyük irin M, Çelikten E, Kalenci D ve ark. Transüda- Eksüda Ay r m nda Çe itli Biyokimyasal Parametrelerin Kar la t rmal Analizi. Tüberküloz ve Toraks Dergisi 2001; 49(3): 380 385.
23- enyi it A, Leblebici H , Babayi it C, Co kunsel M ve ark. Transuda ve Eksuda Ay r m nda Plevral S v Ürik asit Düzeyinin Tan sal De eri. Göztepe T p Dergisi 1999; 14: 94 97.
24- enyi it A, Leblebici H , Babayi it C, ltumur K ve ark. Transuda- Eksuda
Ay r m nda Plevral S v Kolesterol Düzeyinin Tan sal De eri. Solunum Hastal klar 1999; 10: 356 361.
25- Altu N, Alpar S, Y lmaz K, Güler M ve ark. Transuda-Eksuda
Ay r m nda Plevral S v Kolinesteraz Düzeyinin Tan sal De eri. Solunum Hastal klar 2001; 12: 22 25
26- Eid AA, Keddisi JI and Kinasewitz GT. Hypoalbuminemia as a Cause of Pleural Effusions. Chest 1999; 115:1066 1069.
27- Chakko SC. Pleural Effusion in Conjestive Heart Failure (Editorial). Chest 1990; 98: 521 522.
28- Chakko SC, Caldwell SH and Sforza PP. Treatment of Conjestive Heart Failure. Its Effect on Pleural Chemistry. Chest 1989; 95: 798 802. 29- Roden S, Juvin K, Homasson JP and Israel-Biet D. An Uncommon Aetiology of Isolated Pleural Effusion: The Ovarian Hyperstimulation Syndrome. Chest 2000; 118: 256 258.
30- Lossos IS, Breuer R, Intrator O and Sonenblick M. Differential Diagnosis of Pleural Effusion by Lactate Dehydrogenase Isoenzyme Analysis. Chest 1997; 111: 648 651.
31- Tarn AC and Lapworth R. Biochemical Analysis of Pleural Fluid: What Should We Measure Ann Clin Biochem 2001; 38: 311-322.
32- Assi Z, Caruso JL, Herndon J and Patz EE. Cytologically Proved Malignant Pleural Effusions. Distribution of Transudates and Exudates. Chest 1998; 113:1302 1304.
33- American Thoracic Society. Management of Malignant Pleural Effusions. The Official Statement of the American Thoracic Society Was Adopted by the ATS Board of Directors. Am J Respir Crit Care Med 2000; vol:162:1987 2001.
34- Ünlü M, ahin Ü, Akkaya A ve Do an A. Plevral Effüzyonlar n Etyolojisinin Ara t r lmas . Solunum Hastal klar 2001; 12: 212 215 35- Y. Yaz r, C.Ü t p fakültesi dergisi 2007; 29 (2): 7 12
36- Takahashi H,Hattori S,Iwamatsu A,Takizawa H,Shibuya M.A novel snake venom vascular endothelial growth factor (VEGF) predominantly induces vasculer permeability through preferential signaling via VEGF receptor-1. J.Biol Chem 2004; 279: 46304-14.
37- Kendall RL, Wang G and Thomas KA. Identification of a natural
soluble form of the vascular endothelial growth factor receptor, FLT 1, and its heterodimerization with KDR. Biochem Biophys Res Commun 1996; 226: 324 8
38- Ferra N.Role of VEGF in regulation of physiological angiogenesis. Am J Physiol Cell Physiol 2001; C1: 358 66
39- Hanahan D, Folkman j. Patterns and emerging mechanisms of the angogenic switch during tumorigenesis. Cell 1996; 86: 353 364.
40- Poon RT, Fan ST, Wong J. Clinical implications of circulatng
angiogenic factors in cancer patients. Journal of Clinical Oncology. 2001; 19: 1207 1225
41- AngelI-Andersen E, Tretli S, Coleman MP, Langmark F, Grotmol T. Colorectal cancer survival trends in Norway 1958 1997. Eur J Cancer. 2004 Mar; 40(5): 734 42
42- Compton CC. Updated protocol for the examanition of specimens from patientswiht carcinomas of the colon and rectum, excluding carcinoid tumors, Iymphomas, sarcomas and tumors of the vermiform appendix. A basis for checklists. Arc Pathol LamMed 2000; 124: 1016 2533
43- Sugarbaker PH. Sugical Management of Focally Recurrent and Metastatic Colorectal Cancer. In Karakousis CP, Copeland EM, Bland QUI, eds. Atlas of surgical oncology. Philadephi, Saunders, 1995; 45: 671 92
44- Carpelan-Holmstrom M, Louhimo J, Stenman UH, Alfthan H, Jarvinen H, Haglund C. CEA, CA 242, CA 19 9, CA 72 4 and hCGbeta in the diagnosis of recurrent Colorectalcancer. TumourBiol.2004 Sep-Dec; 25 (5 6): 228 34.
45- Markus Guba et al. Vascular endothelial growth factor in colorectal cancer Int J Colorectal Dis 2004; 19: 510 517
46- Folkman J. Tumor angiogenesis therapeutic implications. N Engl J Med 1971; 285: 1182 1186.
47- Folkman j. What is the evidence that the tumors are angiogenesis dependent. J Natl Cancer Inst 1990; 82: 4 6.
48- Hanahan D, Folkman j. Patterns and emerging mechanisms of the angogenic switch during tumorigenesis. Cell 1996; 86: 353 364.
49- Poon RT, Fan ST, Wong J. Clinical implications of circulatng
angiogenic factors in cancer patients. Journal of Clinical Oncology. 2001; 19: 1207 1225
50- Yamamoto Y, Toi M, Kondo S,Matsumoto T,Suzuki H, Kitamura M, Tsuruta K, Taniguchi T. Concentrations of vascular endotelial growth
factor in the sera of normal controls and cancer parients. Clin Cancer Res 1996; 2: 821 6.
51- Kraft A, Weindel K, Ochs A. Vascular endothelial growth factor in the sera and effusions of patients with malignant. and nonmalignant disease. Cancer 1999; 85: 178 87
52- Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Dvorak HF, Senger DR. Increased expression of vascular permeability factor (vascular endotelial growth factor ) and its receptors in breast cancer. Hum Pathol 1995; 26: 86 91
53- Gasparini G, Toi M, Gion M, Verderio P, Dittadi R, Hanatani M, Matsubara I, Vinante O, Bonoldi E, Boracchi P, Gatti C, Suzuki H,
Tominaga T. Prognostic significance of vascular endotelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 1997; 89: 139 47
54- Werther K, Christensen IJ, Brunner N, Nielsen HJ. Soluble vascular. endothelial growth factor levels in patients with primary colorectal. carcinoma. Europan Journal of Oncology 2000; 26: 657 662
55- Ellis LM, Takahashi Y, Liu W, Shaheen RM. Vascular en-. dothelial growt factor in human colon cancer: Biology. and therapeutic implications. The Oncologyst 2000; 5: 11 15
56- Tae K, El-Naggar AK, Yoo E, et all. Expression of vascular. endothelial growth factor and microvessel density in head and neck tumorigenesis. Clinical Cancer Research 2000; 6: 2821 2828
57- Sheidew TG, Hooper PL, Crukley C, Young J, Heatcote JG. .
Expression of vascular. Endothelial growth factor in uveal melanoma and its correlation with metastasis. Br J Ophthalmol 2000; 84: 750 -756 58- Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Dvorak HF, Senger DR. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol. 1993 Nov; 143(5): 1255 62.
59- Bamberger ES, Perrett CW. Angiogenesis in epithelian ovarian cancer. J Clin Pathol 2002; 55: 348 359
60- Guidi AJ, Abu-Jawdeh G, Berse B, Jackman RW, Tognazzi K, Dvorak HF, Brown LF. Vascular permeability factor (vascular endothelial growth
factor) expression and angiogenesis in cervival neoplasia. L natl Cancer Inst 1995; 87: 1237 45
61- Berkman, R A, Merrill, M J, Reinhold, W C, Monacci, W T, Saxena, A, Clark, W C,Robertson JT, Ali IU, Oldfield EH. Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. The Journal of Clinical Investigation 1993; 91: 153 159
62- Matsuya K,Chiba Y, Sasaki M et al. Tumor anjiogenesis as a prognostic marker in operable non-small cell lung cancer. Ann Thorac Surg.1998; 65: 1405 9
63- Carmeliet P,Jain RK. Anjiogenesis in cancer and after diseases. Nature 2000; 407: 249 57
64- Brown LF, Berse B, Jackman RW, Tognazzi K, Guidi AJ, Dvorak HF, Senger DR, Connolly JL, Schnitt SJ. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in
adenocarcinamatozis oh the gastrointestinal tract. Cancer Res 1993; 53: 4727 35
65- Matsuya K, Chiba Y, Sasaki M et al. Tumor anjiogenesis as
aprognostic marker in operable non-small cell lung cancer. Ann Thorac Surg 1998; 65: 1405 9
66- Carmeliet P, Jain RK. Anjiogenesis in cancer and after diseases. Nature 2000; 407: 249 57
67- Cheng D, Rodriquez Rm, Perkett EA, Rogers J, Bienvenu G, Lappalainen U, et al. Vascular endothelial growth factor in pleural fluid. Chest. 1999; 116: 760 765
68- Thickett DR, Armstrong L, Millar AB. Vascular endothelial growth factor (VEGF) in inflammatory and pleural effusions. Thorax. 1999; 54: 707 710
69- Yanagawa H, Takeuchi E, Suzuki Y, Ohmoto Y, Bando H, Sone S. Vascular endothelial growth factor in pleural effusion associated with lung cancer. Cancer Immunol Immunother. 1999; 48: 396 400
70- Verheul HM, Hoekman K, Jorna AS, Smit EF, Pinedo HM. Targeting vascular endothelial growth factor blocade: ascites and pleural effusion. The Oncologist. 2000; 5: S1, 45 50
71- Strizzi L, Catalano A, Vianale G, Orecchia S, Casalini A, Tassi G, et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol. 2001; 193: 469 475
72- Grove CS, Lee YCG. Vascular endothelial growth factor: the key mediator in pleural effusion formation. Curr Opin Pulm Med. 2002; 8: 294 301
73- Kraft A, Weindel K, Ochs A, Marth C, Zmija J, Scuhumacher P, Unger C, Marme D, Gastl G. Vascular endothelial growth factor in the sera and effus ons of patients with malignant and nonmalignant disease. Cancer 1999; 85: 178 87
74- Sack U, Hoffmann M, Zhao XJ, Chan KS, Hui DS, Gosse H, et al. Vascular endothelial growth factor in pleural effusions of different origin. Eur Respir J. 2005; 25: 600 604
75- Bak rc T, Alpar S, Uçar N, Turgut AS, Dursun B, Sertkaya D, ve ark. Plevral efüzyonun ay r c tan s nda [Vascular endothelial growth factor ün ] tan sal de eri. Solunum Hastal klar . 2004; 15: 170 175
76- Cheng D, Rodriquez Rm, Perkett EA, Rogers J, Bienvenu G, Lappalainen U, et al. Vascular endothelial growth factor in pleural fluid. Chest. 1999; 116: 760 765
77- Thickett DR, Armstrong L, Millar AB. Vascular endothelial growth factor (VEGF) in inflammatory and pleural effusions. Thorax. 1999; 54: 707 710
78- Momi H, Matsuyama W, Inoue K, Kawabata M, Ar mura K, Fukunaga H, et al. Vascular endothelial growth factor and proinflammatory cytokines in pleural effusions. Respir Med. 2002; 96: 817 822
79- Nasc mento I, Schaer R, Lemar re D, Fre re S, Paule B, Carvalho S, Meyer R, Scahaer-Barbaros H. Vascular endothelial growth factor (VEGF) levels as a tool to discriminate between malignant and nonmalignant ascites. APMIS 2004; 112: 585 7
80- Izumu K, Sh ro K, Da suke F, Takesh Y, Suguru M, Noburu K.Clinical significance of vascular endothelial growth factor in patients with primary lung cancer. Respirology 2002; 7: 93 98
81- Wei-Guo D, Xiao-Min S, Bao-Ping Y, He-Sheng L, Jie-Ping Y. Role of VEGF and CD44v6 in differentiating bening from malignant ascites. World J Gastroenterol 2003; 9(11): 2596 2600
82- Kaya A, Poyraz B, Celik G, Ciledag A, Gulbay BE, Savas H, Savas I. Vascular endothelial growth factor in bening and malignant pleural
effusins. Arch Bronconeumol. 2005 Jul; 41 (7): 376 9
83- Ishimoto O, Saijo Y, Narumi K, Kimura Y, Ebina M, Matsubara N, Asou N, Nakai Y, Nukiwa T. High level of vascular endothelial growth factor in hemorrhagic pleural effusion of cancer. Oncology.2002; 63(1) :70 5 84- Yabushita H, Shimazu M, Noguchi M, Kishida T, Narumiya H, Sawaguchi K, Noguchi M. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer. Oncol Rep. 2003 Jan-Feb; 10(1): 89 95
85- Yeliz K. Uzmanl k Tezi. 2006
86- Bellamy WT, Richter L, Fruti er Y, Grogan TM. Expression of vascular endothelial growth factor and ts receptors in hematopoietic malignancies. Cancer Research 1999; 59: 728 733
87- Salven P, Teeronhovi L, Joensuu H, A high pretreatment serum vascular endothelial growth factor concentration s associated with poor outcome in non-hodgkin s lymphoma. Blood 1997; 90: 3167 3172